news

  • 6 July 2017
    InDex Pharmaceuticals gets new patent granted in Europe

    InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the European Patent Office. The patent provides additional protection for the use of cobitolimod for the treatment of inflammatory diseases.

    The patent, entitled Compounds and methods for reducing the recruitment and/or migration of polymorphonuclear cells (patent number 2806028), was filed in 2009 and will provide an exclusivity period until October 2029, with the possibility of up to 5 years term extension after market approval.

    “We are pleased that the European Patent Office continues to recognize the innovative nature of cobitolimod for treatment of inflammatory diseases,” said Peter Zerhouni, CEO of InDex Pharmaceuticals. “This patent, along with the previously granted patents and patent applications, is part of our strategy to establish a broad and strong portfolio of intellectual property rights to protect our commercially important discoveries.”